Introduction

Prenatal supplementation with fish oil, rich in n-3 polyunsaturated fatty acids (PUFA) like eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), is recommended since deficiency negatively impacts visual development [1], behavior [2], and cognition [3]. Accordingly, n-3 PUFAs are predicted to provide beneficial effects on infant health and development [4]. The neonatal period is a critical time for development of the intestinal microbiome and the immune system, both of which influence enteric infection susceptibility. We have previously shown that the gut microbiome alters enteric infection in rodents [5]. Of the factors important in shaping the gut microbiome in neonates, breast milk is the most influential [6]. While fish oil supplementation during lactation has been hypothesized to be beneficial on infant development [7], three recent meta-analyses concluded that n-3 PUFAs do not improve physiological outcomes [8,9,10] and may suppress infant immunity [10].

Dietary n-3 PUFAs decrease pro-inflammatory responses [11,12,13,14,15], and supplementation does increase risk for infection (reviewed in [16]). Similarly, we have shown that mice fed fish oil have an altered microbiome and immune cell balance which correlated with fatal sepsis during acute colitis infection [17, 18]. Other rodent studies also found dietary n-3 PUFA increased susceptibility to enteric pathogens like Helicobacter pylori [19], Mycobacterium tuberculosis [20, 21], Listeria monocytogenes [22, 23], Salmonella enterica Enteritidis [24], as well as respiratory pathogens like Paracoccidioides brasiliensis [25] and influenza [26,27,28]. While the former studies were postnatally exposed to fish oil, we have shown that maternal fish oil exposure in rodents resulted in their offspring preprogrammed in their T-cell biology [29], shown to increase susceptibility to colitis [30]. If these findings hold true in humans, the widespread practice of prenatal fish oil supplementation could provoke dysfunctional gut immunity in infants. It is currently unknown how fish oil supplementation affects intestinal colonization by the microbiota during infancy, a critical time when immune tolerance and disease susceptibility patterns develop.

The purpose of this study was to determine if fish oil supplementation during breastfeeding alters infant immunity and gut microbiota. We found that fish oil increased EPA in breast milk corresponding with a decrease in secretory immunoglobulin A (sIgA). These breast milk alterations were associated with an infant microbial composition that predicted reduced immune priming, although there were no changes in self-reported illness between the two groups over a 2-year period. These data suggest that fish oil supplmentation to lactating mothers could be a risk factor for increasing susceptibility to infectious disease in their offspring.

Subjects and methods

Subjects and study design

The research protocol was approved by the UBC Clinical Research Ethics Board and BC Interior Health Ethics Board, and written informed consent was obtained from participants. The trial was conducted according to Declaration of Helsinki principles and registered at https://clinicaltrials.gov (identifier NCT03297801). Study design, recruitment, and subjects are previously described [31]. Briefly, a prospective cohort clinical study was conducted in the Okanagan Valley, BC, Canada where lactating women, who either did or did not supplement their diets with fish oil until their infants were 6 months of age, were recruited. The inclusion criteria required medically certified healthy, full-term infants who obtained over 75% of their daily nutritional intake from breast milk. Preterm infants (≤37 weeks of gestation), infants diagnosed with congenital disorders, or infants introduced to solid foods were excluded. There were no exclusion criteria for the mothers.

One hundred and nine women–infant pairs were recruited, where 18 were excluded and the remaining 91 women (plus one twinset) were included in the final analysis. Forty-seven women self-administered fish oil (on average 500 ± 104 mg EPA and 303 ± 63 mg DHA daily) over the 6-month period and 44 women did not supplement. Information about delivery, antibiotic treatment, anthropometric measurements of the infant, formula intake, vaccination compliance, and demographics of the parents was collected monthly to account for confounding variables. Of the participants included, 7 infants received formula in the hospital and 14 (8 in fish oil and 6 in no fish oil cohort) were partially supplemented with formula milk over the course of the study.

Infant stool and breast milk sample collection

Infant stool samples were collected, stored, and processed as previously described [32], at 1 week of age, and once per month until 6 months. Concurrently, breast milk samples from the mothers were collected the morning of infant stool collection. Before sample collection, wearing sterile gloves, the women cleaned the nipple and surrounding area with warm water and soap, and manually expressed a few drops of milk before collecting 10 mL of foremilk in a sterile tube. The part of the pump that contacted the breast and all the materials used to collect milk were cleansed well and sterilized before each use. All samples were kept at −20 °C for <4 h before being transported to the laboratory using dry ice, and then stored at −80 °C until analysis. Instructions and sterile collection packages for samples were given to the participants every month.

Breast milk fatty acids and dietary intake analysis

To understand the relationship between dietary intake and breast milk fatty acid composition, participants were asked to fill out a 24-h dietary recall each sample collection day to correlate dietary intake and supplementing patterns with the coinciding stool and breast milk samples collected. The dietary questionnaires were assessed by a research dietitian and entered into the NCI automated self-administered (ASA24) dietary assessment tool, a web-based tool for 24-h dietary analysis. The data output from this tool included a summary of dietary nutrients in grams, consumed by the participants. Grams of dietary lipids were converted to relative abundances for direct comparison with the lipids quantified from breast milk. Since dietary recalls are not always good indicators of breast milk fatty acids, the medium- and long-chain fatty acids in breast milk were then chemically quantified using gas chromatography (GC) as previously described [33]. To understand if the two cohorts (mothers self-administering fish oil supplements or not) had different breast milk fatty acids while accounting for infant age, a multivariate analysis of variance (MANOVA) was used. Of the chemically quantified breast milk fatty acids, C13:0, C16:0, C18:1n-9, C18:2n-6, C20:1n-9, C20:5n-3 (EPA), C22:5n-3, and C22:6n-3 (DHA) were selected as explanatory variables based on a priori interest and published animal models. To evaluate the relationship between dietary recalls and quantified breast milk lipids, a pairwise rank correlation followed by a Procrustes rotation and PROTEST permutation test was performed.

Immune function markers

Immune markers, sIgA, IgE, and pro and anti-inflammatory cytokines [granulocyte-macrophage colony-stimulating factor, interferon gamma (IFN-γ), interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-12 (p70), monocyte chemoattractant protein-1, tumor necrosis factor alpha (TNF-α), IL-13, and IL-5] were measured from breast milk and stool supernatant at 1 week, 1 month and 5 months of age, using multiplex assays (Eve Technologies Calgary, Canada).

Sickness incidence

Infant mucosal illness was recorded by primary caregivers for a 2-year time period using an online sickness incidence form as described [31]. Caregivers were asked to complete the online questionnaire each time their infants were sick and were sent monthly reminders.

16S sequencing methods

16S rRNA sequencing was used for bacterial identification [34] of the V3-V4 region, as previously [31]. The 2 × 300 paired end reads were sequenced on a MiSeq system with a V3 chemistry kit at The Applied Genomics Core in Edmonton, AB.

Bioinformatics

All bioinformatics was conducted using Quantitative Insights into Microbial Ecology (QIIME2) [35]. Forward sequences underwent quality filtering, dereplication, chimera removal and denoising using the Deblur plugin [36] with default settings. A Naive Bayes classifier was trained for our primer sets using the Greenegenes (13_8) reference database sequences based on 99% similarity. Taxonomic classification was collapsed and assigned at each phylogenetic level. For phylogenetic-based analyses, MAFFT-aligned [37] sequences were used to produce a phylogeny tree using the fast-tree method [38] with default settings. Microbial data were rarefied to a sampling depth of 4380 for the whole cohort and 5924 for exploratory subset analysis and had an average frequency of 19,738 and 19,330 per sample, respectively.

Statistical methods

Statistical analyses were performed using R [39] version 3.3.0. Results are expressed as mean values ± standard errors of the mean (SEM) unless otherwise stated. For demographic and dietary fish consumption comparisons, Fisher’s exact and chi-squared tests were used. A Pearson correlation analysis assessed associations between dietary intake and breast milk fatty acids. Phyloseq was used to generate alpha diversity indexes and distance matrices based on the rarefied feature table. A pairwise comparison of alpha diversity measures was conducted in QIIME2 followed by a mixed-effects model using lme4 to account for infant sex, mode of delivery (MOD), probiotic supplementation, and infant age. Microbial communities in the fish oil groups were visualized using a PCoA on a Bray–Curtis dissimilarity matrix the Vegan package and visualized using ggplot2. LEfSe evaluated statistical significance and effect size of taxa abundances [40] where features with fewer than ten counts across all samples or appearing in fewer than five samples were removed. A multiclass comparison was performed using the Kruskal–Wallis test (α = 0.05), and a linear discriminant analysis (LDA) score for discriminative features set to 2.0. The biologically relevant features were visualized in a cladogram. BugBase [41] determined if fish oil associated with any predictive phenotypes and the type of bacteria was predicted using VSEARCH [42] at 97% similarity. Statistical analysis of the predictions was done using a pairwise Mann–Whitney–Wilcoxon test.

Relationship between breast milk fatty acids and the infant bacteriome

A multiple regression analysis was conducted using an open source R code [43]. Only participants with complete data set including GC-quantified breast milk and infant stool samples at months 2, 3, and 4 were assessed resulting in 24 subjects for this exploratory analysis. All the included infants in this subset analysis were exclusively breast fed. Potential predictors of microbial composition were screened using a Spearman correlation matrix and fatty acids that exhibited a significant correlation with alpha diversity species richness were included. Multicollinearity between fatty acids was checked using the variable inflation factor index with a maximum cut-off score of 10. The microbial communities were analyzed using two complementary multivariate approaches: (1) constrained ordination using RDA, focusing on community composition differences in relation to predictors of interest, and (2) multiple generalized linear models. Because of our interest in age effects, each infant age was assessed separately while acknowledging increased potential for type-1 errors. Fatty acids included: tridecylic acid (C13:0), palmitic acid (C16:0), oleic acid (C18:1n-9), linoleic acid (C18:2n-6), EPA (C20:5n-3), docosapentaenoic acid (C22:5n-3), and DHA (C22:6n-3). Abundance data at each taxonomic level along with the fatty acids were Hellinger transformed [44]. Variable selection in RDA was implemented using the ordistep function in Vegan version 2.4–4, using both forward and backward stepwise inclusion. Features with a significant correlation coefficient based on the first two axes (evaluated at a Bonferroni-adjusted alpha level) were displayed on the RDA plots with type II scaling. To evaluate the association of genus abundance with explanatory variables, we implemented multiple negative binomial GLMs using the mvabund package [45] version 3.12.3, which uses a series of univariate F-tests of the effects of predictor variables on the abundance of each taxon, while adjusting for multiple testing. Residual diagnostics were used to assess regression assumptions. Microbes were filtered and any taxa that made up <0.1% of the total count and occurring in <75% of samples were removed (cf. [46]). Seven taxa met the inclusion criteria at 3 months of age and four taxa met the inclusion criteria at 4 months of age and were included in the model. To explore the relationship between the microbial communities and the breast milk fatty acids over time and to test the significance of the identified relationship, Procrustes rotation and PROTEST permutation tests were implemented in Vegan based on the RDAs which showed a significant accord between breast milk fatty acids and infant stool microbial communities [47, 48]. A LDA using the MASS [49] package in R was used to determine whether the quantified immune markers could discriminate between the two supplementing groups. The collected data sets were first split into a training set and a test set. We trained the LDA model and then validated our results using the test data set to predict the supplementing group. This was followed by an MANOVA with Wilks’ lambda test for comparisons. Immune data were first “scaled” in R using default settings to accommodate differences in measurements. IFNγ, IL-6, IL-8, IL-10, IL-12, TNFα, IL-5, and sIgA were included in the LDA model and MANOVA at 1 and 5 months. Given sample size limitations, at 1 week of age the immune model was reduced to IL-10 and sIgA, based on findings at 1 and 5 months. The remaining immune cells were tested using Student’s t tests. Non-detects were treated as zero values. For group comparisons of breast milk lipids, an MANOVA with Wilks’ lambda test was ran on “logit” transformed lipid proportions at each age. In all cases, model fit was visually inspected using diagnostic plots of the residuals.

Results

The study aims were to: understand how habitual fish oil supplementation during lactation alters bioactive constituents in breast milk and infant stool; determine if fish oil supplementation was associated with changes to the infant microbial composition; explore the relationship between specific breast milk fatty acids and infant microbial diversity; and determine if fish oil supplementation corresponded with altered parent-reported incidence of infection by 2 years of age. The flow of participants throughout the trial is detailed in Fig. S1. Of the 91 mothers to complete the study, 62 provided at least one breast milk sample over a 6-month period for paired comparisons. Participants were mostly well-educated and of Euro–Canadian descent with similar household income, maternal age, gestational age, and infant birth characteristics between the two groups (Table S1).

Fish oil supplementation associates with increased n-3 PUFA in breast milk and decreased defensive inflammation

No differences in dietary fish consumption were reported by the participants. The Procrustes rotation analyses and protest tests showed a significant accord between mothers reported dietary intake and fatty acids quantified in breast milk (Table 1). This suggested that the overall profile of lipid intake data of mothers from the questionnaire correlated with the overall profile of lipids measured in their breast milk. Without adjusting for multiple testing, pairwise rank correlations revealed significant associations between maternal dietary consumption and breast milk fatty acids, but the results were inconsistent over time (Table 1). Therefore, all forthcoming analyses using breast milk fatty acids were conducted on the GC-quantified fatty acids.

Table 1 Comparison of reported maternal nutrient intake 24 h prior to breast milk collection and GC quantified breast milk fatty acids.

Assessment of the breast milk lipid profile (Fig. 1a) revealed that participants supplementing with fish oil (500 ± 104 mg EPA and 303 ± 63 mg DHA daily average) had a higher proportion of EPA (C20:5n-3) in their breast milk at 1, 4, and 5 months postpartum despite no detectable differences in DHA (C22:6n-3) or alpha-linolenic acid (C18:3n-3) (Table S2). The mothers supplementing habitually with fish oil had lower amounts arachidonic acid (C20:4n-6) at 1 week and 2 months of breastfeeding as well as eicosatrienoic acid (C20:3n-3) at 1 week, 1, 3 and, 4 months of breastfeeding. Therefore, self-administration of fish oil supplements correlated with changes to the bioactive constituents in breast milk. The percent compositions of all quantified breast milk fatty acids are available in Table S2.

Fig. 1: Fish oil supplements taken during lactation alter the lipid profile in the breast milk and impair defensive immunity.
figure 1

a Compared with the non-fish oil group, breast milk of participants self-administering fish oil supplements during lactation had a significantly lower proportion of eicosatrienoic acid (C20:3n-3) and arachidonic acid (C20:4n-6) in their breast milk and a higher proportion of eicosapentaenoic acid (EPA, C20:5n-3), an omega-3 PUFA present in fish oil (n = fish oil: no fish oil at 1 week (5:5), 1 month (15:13), 2 months (20:19), 3 months (23:19), 4 months (28:22), 5 months (28:19), 6 months (12:4)). There were no differences in docosahexaenoic acid (DHA, C22:6n-3) after correcting for multiple testing. b The prevalence of breast milk sIgA was similar between the two cohorts at 1 week and 1 month of age. In contrast, at 5 months the no fish oil group had higher breast milk sIgA (22:18). IgE was not affected by fish oil exposure at 5 months. *P ≤ 0.05 by MANOVA.

In addition to changes in fatty acid percent composition, changes to breast milk immune markers were associated with fish oil supplementation (Table S3). LDA predicted the supplementing group at 1 month with a 61.5% accuracy (P = 0.05) based on IFN-γ, IL-5, IL-6, IL-8, IL-10, IL-12, TNF-α, and sIgA concentrations in breast milk. The groups were different predominantly due to the higher anti-inflammatory cytokine, IL-10 (P = 0.058) in the fish oil group. At 5 months, the LDA model predicted the supplementing group with a 62.5% accuracy (P = 0.05) between the two cohorts. Results from the MANOVA showed that the fish oil group had lower sIgA, an important mucosal defense factor (Fig. 1b). In contrast, IgE, which plays a role in allergies [50], was similar between the two groups. IL-10 and sIgA were included in the LDA model at 1 week and they predicted the fish oil group with a 75% accuracy (P = 0.16). Overall, the LDA was able to discriminate between the two groups based on quantified immune markers where fish oil supplementation was associated with decreased protective sIgA and increased anti-inflammatory IL-10.

Habitual fish oil supplementation augments bacteria with reduced immune priming potential

Fecal bacterial diversity was assessed to determine if fish oil supplementation associated with changes to the infant microbial composition. The mixed-effects model found no overall difference in alpha diversity measures between the supplemented and non-supplemented cohorts (Fig. 2a); however, pairwise comparisons found lower Shannon’s diversity and Pielou’s evenness, two alpha diversity indexes, at 5 months in the fish oil group (Table S4). Pairwise comparisons of weighted and unweighted UniFrac distance matrices revealed marginal (P = 0.08) differences in the presence of fecal bacteria between the two infant groups at 1 week of age only. This observation was followed-up with LEfSe [40], which showed infants in the fish oil group had higher abundances of Bifidobacterium, Lactobacillus, and Bacteroides spp. in stool, whereas the non-fish oil group had an abundance of Firmicutes phyla (Fig. 2b). Collectively, these data show a positive association between fish oil supplementation and bacteria commonly present in high abundances in breast-fed and vaginally birthed babies that have been shown to induce anti-inflammatory responses [51, 52].

Fig. 2: Fish oil supplements taken during lactation increase anti-inflammatory microbes and alter bacterial taxa succession.
figure 2

a Alpha diversity among supplementing groups over a 6-month period using Shannon, Faith’s PD, Pielou’s Evenness, and Observed Species Richness measures, *P < 0.05. b LEfSe results comparing stool from infants in the fish oil (n = 6) group and no fish oil (n = 7) group at 1 week of age. The cladogram reports the taxa showing different abundance values according to LEfSe. Colors indicate the lineages that are encoded within corresponding samples.

Breast milk EPA and DHA predict infant gut microbial diversity

Breast milk DHA corresponds with lower alpha diversity measures in infants

To gain a better understanding of which specific breast milk fatty acids influence the infant fecal microbiota, eight breast milk fatty acids of a priori interest were included as potential predictors of alpha diversity on corresponding infant stool sets at months 2, 3, and 4. In addition, infant sex and MOD were included as they have previously been shown to influence microbial diversity. We constructed separate multiple regressions for each diversity index, which exhibited collinearity (Figs. S2S4). After prescreening, all the potential predictors using a Spearman correlation analysis, DHA (C22:6n-3) in breast milk, infant sex, and MOD were included in the multiple regression model (Table 2). At 2 months of age, species richness was negatively associated with breast milk DHA and vaginal deliveries (Fig. 3a). Faith’s PD similarly showed a negative association with DHA but not infant sex or MOD. None of the predictors were associated with Shannon diversity or Pielou’s Evenness at 2 months of age. At 3 months, vaginal deliveries negatively associated with Shannon diversity, but not species richness, Pielou’s evenness, or Faith’s PD (Fig. 3b). In contrast, Faith’s PD positively correlated with male infants and the percent composition of breast milk palmitic acid (C16:0). At 4 months, DHA was negatively associated with species richness, Faith’s PD, and Shannon diversity. Male sex was likewise positively associated with species richness and Faith’s PD. MOD did not reach statistical significance (Fig. 3c). Overall, breast milk DHA corresponds with lower alpha diversity measures over time in the developing microbiome of infants.

Table 2 Multiple regression summary of species richness, evenness, and Faith’s PD data.
Fig. 3: Results of a multiple regression model show a significant association between alpha diversity measures and four of ten predictors of interest.
figure 3

a At 2 months of age, Faith’s PD and Species richness negatively correlate with breast milk DHA (C22:6n-3) levels. Species richness also significantly correlates with MOD. b At 3 months, Faith’s PD positively correlates with sex and palmitic acid (C16:0). Shannon diversity significantly correlates with MOD at 3 months of age. c Correlations among species richness, Faith’s PD and Shannon diversity show a negative association with DHA at 4 months. Faith’s PD also correlates with sex. Shaded areas represent 95% confidence intervals (n = 24).

Overall gut bacterial community composition is dictated by EPA and DHA

Overall, ~84 genera from nine phyla were represented across all participants (Table 3). The fish oil group included representation from 57.7 ± 3.1 genera, while the no fish oil group was made up of 58.0 ± 1.5 genera at the reported ages. None of the breast milk fatty acids were selected as meaningful explanatory variables of infant fecal genera at 2 months of age, but oleic acid (C18:1n-9), EPA (C20:5n-3), DHA (C22:6n-3), and MOD were selected at 3 months of age, and tridecylic acid (C13:0), EPA, DHA, and MOD were selected at 4 months of age as determined by Monte Carlo Permutation Procedure at 1000 permutations (Table S5). In all, 14.52% and 13.34% of the total variation in taxon composition was attributed to these fatty acids as explanatory variables at ages 3 and 4 months, respectively (Fig. 4). Genera that were significantly correlated with at least one of the first two RDA axes are highlighted. The results illustrate that EPA in breast milk correlated with Bifidobacterium, and Streptococcus spp. and MOD correlated with Bacteroides. While DHA was selected as a significant predictor at both months 3 and 4, it did not consistently align with any of the selected genera. At 3 months DHA aligned with Enterobacteriaceae (Fig. 4a) but this finding was not apparent at 4 months (Fig. 4b). Oleic acid correlated with Lactobacillus spp. at 3 months and tridecylic acid with Bifidobacterium and Streptococcus spp. at 4 months, similar to EPA. Clostridium spp. correlated with RDA1 but was not associated with the predictor fatty acids included in our model. As EPA was increased in the breast milk of supplementing mothers, and this was validated using LEfSe. As expected, LEfSe shows an increase in Bifidobacterium spp. in the fish oil supplemented cohort, which had increased breast milk EPA (Fig. 4c). In order to explore the relationship between the microbial community and breast milk fatty acids for both 3- and 4-month-old infant data and to test the significance of the identified relationships, Procrustes rotation and PROTEST permutation test were applied to the RDA ordination results. The correlation diagnostics gave a Procrustes sum of squares value (m12) of 0.55 and a correlation in symmetric Procrustes rotation of 0.6682 which was significant (P = 0.001) when using 3- and 4-month RDA scores, respectively. This suggests a high degree of correspondence between the 3- and 4-month assemblages. Overall, breast milk EPA consistently aligns with abundances of Bifidobacterium, and MOD aligns with Bacteroides at 3 and 4 months of age. Oleic acid, tridecylic acid, and DHA were also highlighted as potential predictors of microbial diversity but the results were not consistent over time.

Table 3 Identified known taxa across supplementing groups.
Fig. 4: Breast milk EPA (C20:5n-3) associates with anti-inflammatory microbes such as Bifidobacteria and Lactobacillus spp., whereas DHA (C22:6n-3) aligns with Enterobacteriaceae.
figure 4

Bacterial abundance RDA correlation biplots constrained by selected explanatory variables at a 3 months of age and b 4 months of age. The groups and explanatory variables and genera plots are presented separately for clarity; however, they are derived from the same RDA model. RDA1 and RDA2 which explain over 14.52 % and 13.34% of total variation in beta diversity, respectively, are plotted. The global model’s P value was calculated using the Monte Carlo Permutation Procedure (MCPP). Subjects are color coded according to whether or not the mother supplemented with Fish oil for illustrative purposes only as groupings were not included in the model. P ≤ 0.05 is considered significant (n = 24). c LEfSe results comparing stool from infants in the fish oil (n = 24) group and no fish oil (n = 24) groups at 3 (left) and 4 (right) months of age show an increased abundance of anti-inflammatory bacteria such as Bifidobacteria spp. in the fish oil cohort. The cladogram reports the taxa showing different abundance values according to LEfSe. Colors indicate the lineages that are encoded within corresponding samples.

Fish oil predicts reduced commensal colonization resistance

We furthered our exploratory analysis by assessing whether fish oil was associated with any predicted high-level phenotypes. The results revealed a predicted increase in the relative abundance of Gram-positive bacteria in the fish oil cohort and a corresponding decrease in Gram-negative bacteria at 2 months of age (Fig. 5a, b). In addition, our findings indicate that fish oil supplementation corresponded with lower abundances of biofilm forming, mobile element containing, and stress tolerant bacteria at 2 months of age (Fig. 5c–e).

Fig. 5: Fish oil supplementation during lactation increases the predicted relative abundance of commensal virulence traits involved in pathogen colonization resistance but does not associate with rates of infections in infants.
figure 5

BugBase predicted relative abundance of a Gram-positive bacteria, b Gram-negative bacteria, c biofilms formers, d stress tolerant bacteria, and e bacteria containing mobile elements at 2, 3 and 4 months of age. Values are expressed as mean values (n = 24 per group). An asterisk indicates P < 0.05 using a pairwise Mann–Whitney–Wilcoxon test. f Infection rates and duration were not different between the two cohorts.

Fish oil supplementation does not associate with changes to rates of infections in infants

Nineteen mothers in the fish oil cohort and ten mothers in the no fish oil cohort participated in a 2-year follow-up on their infant’s health. Unlike the mothers’ breast milk, infant stool did not reveal any differences in cytokines, sIgA, or IgE expression at 1 week, 1, or 5 months of age (Table S3) and the LDA which incorporated immune markers collectively was unable to predict the supplementing group at any time point. Similarly, both incidences of mucosal infections and time required to clear mucosal infections (duration) were statistically insignificant between the groups (Fig. 5f). On average, the mothers supplemented with fish oil reported that their infant was sick 3.45 ± 0.61 times over a 2-year period, with the non-supplementing group reporting 4.38 ± 1.52 times. The fish oil and no fish oil infants took an average of 8.07 ± 1.12 and 5.86 ± 1.43 days to clear their infections, respectively.

Discussion

While maternal fish oil supplementation is widely believed to support infant health, the effect on gut health is relatively unknown. This is the first study aimed at investigating the effects of habitual fish oil supplementation on breast milk fatty acid composition and the infant microbial composition from birth until 6 months of age with corresponding health outcomes up to 2 years. Here we show that women supplementing with fish oil associate with decreased defensive inflammatory responses and produce an infant gut bacteriome with potentially less capacity to prime the pro-inflammatory branches of the immune system in their infants. Overall, habitual fish oil supplementation was not associated with clear and better health outcomes in supplemented infants.

Fish oil has two major n-3 PUFAs important for infant development: EPA and DHA. A recent systematic review [53] showed that with one exception [54], controlled studies consistently supplement mothers with higher DHA than EPA, and often with DHA exclusively. However, in this study it was apparent that Canadian mothers supplement with higher EPA than DHA, resulting in relatively higher proportions of EPA in breast milk. In this study, we show habitual administration of fish oil correlated with a greater proportion of breast milk EPA, accompanied by a marked decrease in the proportion of AA throughout lactation when compared with the non-supplementing participants, similar to previous studies [55, 56]. Fish oil supplementation also resulted in less eicosatrienoic acid, a less reported n-3 PUFA. While eicosatrienoic acid has widely been considered a dead-end product, recent studies show desaturation of eicosatrienoic acid yields eicosatetraenoic acid (C20:4n-3) as well as immediate eicosanoid precursors [57], which is consistent with the idea that fish oil decreases inflammatory mediators [58].

This study shows that fish oil supplementation, primarily driven by EPA, decreases defensive inflammation in breast milk. Breast milk supplies the first source of antigen-specific immune protection in the intestinal tract of infants in the form of sIgA. sIgA has been shown to shape the composition of the gut microbiome and prevent the translocation of aerobic bacteria from the neonatal gut into lymph nodes [59]. This protects against inflammation and promotes intestinal barrier function. This study found that breast milk sIgA was decreased in the supplementing mother’s breast milk at 5 months postpartum and this corresponded with increased levels of EPA. This is similar to previous studies showing decreased breast milk concentrations of sIgA corresponding with increased breast milk n-3 PUFA through fish consumption [60]. In addition, the anti-inflammatory cytokine IL-10 was increased in mother’s breast milk who supplemented with fish oil. IL-10 inhibits the activity of pro-inflammatory Th1 cells, NK cells, and macrophages, leading to impaired pathogen control and clearance which can result in persistent asymptomatic infections including Candida albicans and mycobacterial infections (reviewed in [61]). Overall, fish oil supplementation decreased critically important defense factors in one of the only sources the infants get during early life.

In addition to reducing breast milk defense factors, there were limited differences in the infant gut bacteriome. Fish oil supplementation was associated with higher Bifidobacteria and Lactobacillus spp. at 1 week of age with no overall differences in fecal alpha diversity. To understand which specific breast milk fatty acids are good predictors of microbial diversity, complete data sets at months 2, 3, and 4 were reassessed according to mothers’ breast milk fatty acid profile. Results from a regression model showed that higher levels of DHA in breast milk negatively correspond with fecal species richness and phylogenetic diversity at 2 and 4 months of age. DHA proportions in breast milk were likewise shown to contribute to microbial assemblages in infant stool at 3 and 4 months of age. Although none of the selected breast milk fatty acids correlated with bacterial abundance at 2 months, our Procrustes results suggest a high degree of concordance between the environmental variables EPA and DHA on microbial assemblages at 3 and 4 months. One notable finding of this study is that n-3 PUFAs illicit a stronger effect on the infant bacteriome than other more abundant breast milk fatty acids. In fact, the global RDA model selected both EPA and DHA as meaningful explanatory variables alongside MOD, which is a known significant contributor to microbial diversity. Similar to the results seen in the fish oil group at 1 week, the RDA results investigating the association between individual fatty acids and the infant gut further showed that EPA in breast milk uniquely posed a significant association with members of Bifidobacterium, Lactobacillus, and Streptococcus, independent of DHA. This was verified by LEfSe that showed an increase in Bifidobacterium spp. in the fish oil supplementing subset at 3 and 4 months of age. In support of previous literature, our study shows that Bacteroides spp. were associated with infant MOD [62] and that caesarian sectioned babies have higher alpha diversity in early life [63]. We also found that female infants had lower alpha diversity at 3 and 4 months of age. These findings strongly mimic rodent models performed in our lab, which showed n-3 PUFA supplementation increases gut microbes such as Lactobacillus and Bifidobacteria spp. [17].

Previous studies have shown that Lactobacillus and Bifidobacteria spp. have the ability to induce anti-inflammatory response in their host [51, 64]. Generally, these species are considered beneficial; however, they proved unfavorable during enteric infection which resulted in murine sepsis and mortality [17]. In this study, we did not see any evidence that infants in the fish oil cohort had altered immune function; however, predicted microbial phenotypes suggested an inverse relationship between fish oil and biofilm formation, mobile elements and stress tolerance. While these virulence traits are usually associated with bacterial pathogens [65], it is plausible that commensal bacteria with these predictive traits may benefit the infant given the immune system is primed and developed during this period of time. For example, since commensal biofilms occur in close juxtaposition to host epithelium, it could indicate that these bacteria interact to a greater extent with the immune system than their planktonic counterparts and are more resistant against pathogen colonization [66]. In support of this, the gut epithelia contacted by commensal bacteria generate reactive oxygen species which could account for increased stress tolerant bacteria in this group. Microbial-elucidated reactive oxygen species can increase cellular proliferation in the intestine and modulate innate immune signaling [67]. Germ-free models have shown that in the absence of microbial exposures, the immune system is immature (reviewed here [68]) and that some, but not all, bacteria act to “mature” the immune system. For instance, previous studies have shown that Bifidobacterium longum was not able to induce the production of RegIIIγ by Paneth cells, whereas Bacteroides thetaiotaomicron was [69, 70]. Thus, the predicted decrease in biofilm formation, mobile elements, and stress tolerant bacteria in the fish oil cohort could contribute to decreased immune priming. Despite this, we did not observe any differences in infant susceptible to infection. A possible explanation for this might be that none of the children in this study were critically ill or exposed to bacterial pathogens. The “anti-inflammatory” nature of n-3 PUFA may only be detrimental when exposed to infectious pathogens.

Overall, our findings underscore that different types of breast milk fatty acids impart varying effects on the human infant bacteriome. While this was an observational prospective study, we demonstrated that supplementing with fish oil increased the percent composition of EPA in breast milk, which was associated with decreased defensive inflammatory mediators in the infant’s nutrition source and this was associated with a gut microbiome that had reduced immune priming capability and predicted less colonization resistance. Given that fish oil appears to alter the infant microbial composition through changes in breast milk, and that the microbiota is intricately linked to infant health, we recommend large scale epidemiological studies to clarify whether early fish oil exposures alter infectious disease susceptibility including persistent asymptomatic chronic infections.